Clinical Impact of Continuous Dasatinib Administration on the Prognosis of Patients With BCR::ABL1 Acute Lymphoblastic Leukemia: Result of the Prospective MRD2014 Study Conducted by Fukuoka Blood and Marrow Transplantation Group ( FBMTG )
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14407 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Koji Nagafuji und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology & Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan. Hauptthemen laut MEDLINE: Dasatinib, Fusion Proteins, bcr-abl, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Aim
To assess the efficacy of continuous dasatinib in improving outcomes for adult patients with BCR::ABL1 ALL.
Methods
The prospective, multicenter ALL/MRD2014 trial introduced a modified protocol compared to the MRD2008 trial, incorporating continuous dasatinib use and reduced chemotherapy intensity.
Results
Among the 164 adult ALL patients enrolled (2014–2019), 61 were Philadelphia‐positive (Ph+) (median age 50 years; 38 males, 23 females). Post‐induction, 96.7% achieved complete remission (CR). The 3‐year event‐free survival (EFS) and overall survival (OS) were 51% and 76%, respectively. Patients undergoing allo‐HSCT in CR1 had improved outcomes, with a 3‐year EFS of 64% and OS of 87%. MRD‐negative patients before transplantation exhibited superior survival (EFS: 71% vs. 29%; OS: 94% vs. 57%). Comparison with the MRD2008 trial revealed similar outcomes, with the MRD2014 trial achieving a 3‐year EFS of 51% and OS of 76% vs. 52% and 84% in MRD2008. Although not statistically significant, the MRD2014 trial showed trends of increased relapse (CIR: 39% vs. 26%, p = 0.305) and reduced non‐relapse mortality (NRM: 10% vs. 21%, p = 0.181).
Conclusion
The ALL/MRD2014 trial underscores the importance of MRD status and allo‐HSCT in Ph+ ALL. Continuous dasatinib‐based regimens offer favorable outcomes in MRD‐negative patients. Trial Registration This study was registered with the UMIN Clinical Trials Registry (UMIN‐CTR), number UMIN000012382
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology & Oncology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
- Department of Hematology, Imamura General Hospital, Kagoshima, Japan.
- Hematology/Respiratory Medicine, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
- Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
- Department of Hematology, HaraSanshin General Hospital, Fukuoka, Japan.
- Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
ORCID-Profile: Koji Nagafuji
Zitieren
APA
Nagafuji, K., Ito, Y., Miyamoto, T., Eto, T., Kamimura, T., Kato, K., Miyazaki, Y., Wake, A., Kohno, K., Takase, K., Imamura, Y., Uchida, N., Tanimoto, K., Kawano, N., Kurokawa, T., Kondo, Y., Fujisaki, T., Tsukada, J., Yonemoto, K., & Akashi, K. (2025). Clinical Impact of Continuous Dasatinib Administration on the Prognosis of Patients With BCR::ABL1 Acute Lymphoblastic Leukemia: Result of the Prospective MRD2014 Study Conducted by Fukuoka Blood and Marrow Transplantation Group ( FBMTG ). European Journal of Haematology. https://doi.org/10.1111/ejh.14407
Vancouver
Nagafuji K, Ito Y, Miyamoto T, Eto T, Kamimura T, Kato K, et al. Clinical Impact of Continuous Dasatinib Administration on the Prognosis of Patients With BCR::ABL1 Acute Lymphoblastic Leukemia: Result of the Prospective MRD2014 Study Conducted by Fukuoka Blood and Marrow Transplantation Group ( FBMTG ). European Journal of Haematology. 2025. doi:10.1111/ejh.14407
BibTeX
@article{Nagafuji2025,
author = {Nagafuji, Koji and Ito, Yoshikiyo and Miyamoto, Toshihiro and Eto, Tetsuya and Kamimura, Tomohiko and Kato, Koji and Miyazaki, Yasuhiko and Wake, Atsuhi and Kohno, Kentaro and Takase, Ken and Imamura, Yutaka and Uchida, Naoyuki and Tanimoto, Kazuki and Kawano, Noriaki and Kurokawa, Toshiro and Kondo, Yukio and Fujisaki, Tomoaki and Tsukada, Junichi and Yonemoto, Koji and Akashi, Koichi},
title = {Clinical Impact of Continuous Dasatinib Administration on the Prognosis of Patients With BCR::ABL1 Acute Lymphoblastic Leukemia: Result of the Prospective MRD2014 Study Conducted by Fukuoka Blood and Marrow Transplantation Group ( FBMTG )},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14407}
}
EUVIMED